JPRN-jRCTs021180042已完成2 期
The effectiveness and safety of cocurrent chemoradiation therapy for squamous cell carcinoma of vulva; P2 Study - CCRT for VSCC
Futagami Masayuki0 个研究点目标入组 18 人开始时间: 2019年3月26日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 18
研究概览
简要总结
The antitumor effect, which is the primary endpoint, is extremely high, and the tumor control rate is higher than that of the conventional method. The 2-year survival rate is 57.1% even in stages III and IV, but long-term follow-up has not been performed, so this is for further study. Regarding safety, there were few serious adverse events and it was highly possible that it could be done safely.
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 20age old 至 <= 79age old（—）
- 性别
- Female
入选标准
- •1) Patients with a histiological diagnosis of squamous cell carcinoma of vulva
- •2) Patients with measurable or evaluable lesions
- •3) First treatment case
- •4) Age is from 20 to 79 years old
- •5) ECOG Performance Status is 0-2
- •6) Major organ function is maintained
- •7) Patients who signed informed consent
排除标准
- •1) Patients who have received prior chemotherapy or/and
- •irradiation therapy
- •2) Patients with active synchronous cancer
- •3) Patients with active infection
- •4) Patients with severe complication, bronchial asthma, interstitial pneumonia, ischemic heart disease, diabetic mellitus and arrhythmia
- •5) Patients with massive pleural effusion or asites
- •6) Patients with history of hypersensitivity reaction
- •7) Patients with pregnant or lactating
- •8) Patients who is difficult to treat and follow in this study
- •9) Patients who are not eligible in this study by study chair or study co-chair.
研究者
相似试验
招募中
不适用
Chemotherapy and Pelvic Hypofractionated Radiation Followed by Brachytherapy for Cervical CancerCervical CancerNCT04070976National Institute of Cancerología82
尚未招募
2 期
Chemotherapy Plus Bevacizumab and Anti-PD-1 Followed by Induction Therapy of Chemotherapy Plus BevacizumabMetastatic Colorectal CancerMSSNCT06415851Zhangfa Song36
招募中
2 期
Concurrent Chemoradiotherapy Combined With Immunotherapy in Patients With Potentially Resectable Pancreatic CancerPancreatic CarcinomaNCT05634564The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School62
招募中
不适用
Tumor Control, Treatment Toxicity, Quality of Life and Bio-Imaging Repository Databank (TQ-BIRD) for Cancer PatientsCancerNCT05061342Fengming Kong5,000
终止
2 期
Ph II Concurrent Chemo t/Docetaxel/Carboplatin/Radio Therapy-consolidation t/Locally Adv Inoperable Non-Small Cell Lung Cancer (NSCLC)Lung CancerNCT00664105Vanderbilt-Ingram Cancer Center63